Baxter International, Inc. (NYSE: BAX) reported Q2 EPS of $1.26, 4 cents better than the analyst estimate of $1.22. Revenue for the quarter came in at $4.3 billion versus the consensus estimate of $4.12 billion.

Baxter International, Inc. sees Q3 2014 EPS of $1.28-$1.32, versus the consensus of $1.32. The company expects sales growth of approximately 12 to 13 percent.

Baxter now expects sales growth for full-year 2014 of 10 to 11 percent, before the impact of foreign exchange. Also for the full year, Baxter expects earnings, before special items, of $5.10 to $5.20 per diluted share and cash flows from operations of approximately $3.5 billion, excluding cash costs related to the spin-off of the biopharmaceutical business.

For earnings history and earnings-related data on Baxter International, Inc. (BAX) click here.